Pharmaceuticals

Global Conjugate Vaccine Market Set for Strong Expansion, Reaching $38.54 Billion With 12.8% CAGR by 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the conjugate vaccine market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Conjugate Vaccine Market?

The conjugate vaccine market has experienced significant expansion recently. This market is projected to expand from $21.26 billion in 2025 to $23.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. Factors contributing to its historical growth include government-led immunization initiatives, a high prevalence of bacterial infections, backing from global health organizations, the proven efficacy of conjugate vaccines, and a rising pediatric population.

The conjugate vaccine market is projected for substantial expansion in the coming years, with its size forecast to reach $38.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. This anticipated growth stems from several factors including the increasing need for combination vaccines, the broadening of adult vaccination initiatives, enhanced investment in vaccine research and development, a heightened emphasis on combating antimicrobial resistance, and improvements in cold chain infrastructure. Key trends observed during this period involve the expansion of pediatric immunization programs, a growing acceptance of multivalent conjugate vaccines, a stronger emphasis on achieving long-term immunogenicity, an increase in public-private collaborations for vaccine development, and innovations in carrier protein technologies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Which Drivers Are Supporting The Rise Of The Conjugate Vaccine Market?

The expanding occurrence of infectious diseases is projected to drive the growth of the conjugate vaccine market. These conditions are caused by disease-causing microorganisms such as bacteria, viruses, parasites, or fungi, and can be transmitted directly or indirectly between people, from animals to humans, or through environmental factors. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among vulnerable groups like infants and young children. For instance, information from the Centers for Disease Control and Prevention, a US-based government entity, shows that the count of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing an increment of 1,295 cases. Furthermore, the rate of incidence went up from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Thus, the increasing incidence of infectious diseases is fueling the development of the conjugate vaccine market.

What Leading Segments Are Studied In The Conjugate Vaccine Market?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Which Trends Are Expected To Influence The Conjugate Vaccine Market In The Upcoming Years?

Leading companies in the conjugate vaccine market are prioritizing the development of advanced conjugate vaccines aimed at providing more comprehensive defense against numerous pneumococcal serotypes, thus lessening the disease burden on susceptible populations. These next-generation conjugate vaccines operate by attaching bacterial polysaccharides to carrier proteins to enhance the immune response, particularly in infants and immunocompromised individuals, thereby offering superior protection, longer-lasting immunity, and greater effectiveness compared to traditional vaccines. For example, in August 2025, Pfizer Ltd., an India-based pharmaceutical company, introduced its cutting-edge 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India, consequently strengthening its conjugate vaccine portfolio by delivering broader protection against pneumococcal disease and fostering improved public health outcomes.

Which Leading Companies Dominate The Conjugate Vaccine Market Share?

Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

How Does The Conjugate Vaccine Market Perform Across Major Global Regions?

North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Conjugate Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Browse Through More Reports Similar to the Global Conjugate Vaccine Market 2026, By The Business Research Company

Conjugate Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Vaccine Adjuvants Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-adjuvants-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795